Tumor cell agglutination and not solely cytokine release as mechanism of adverse reactions during anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) treatment
Open Access
- 15 September 2001
- journal article
- Published by American Society of Hematology in Blood
- Vol. 98 (6) , 1991-1992
- https://doi.org/10.1182/blood.v98.6.1991
Abstract
No abstract availableKeywords
This publication has 4 references indexed in Scilit:
- Cytokine-Release Syndrome in Patients With B-Cell Chronic Lymphocytic Leukemia and High Lymphocyte Counts After Treatment With an Anti-CD20 Monoclonal Antibody (Rituximab, IDEC-C2B8)Blood, 1999
- Rituximab Therapy in Hematologic Malignancy Patients With Circulating Blood Tumor Cells: Association With Increased Infusion-Related Side Effects and Rapid Blood Tumor ClearanceJournal of Clinical Oncology, 1999
- Leukostasis followed by hemorrhage complicating the initiation of chemotherapy in patients with acute myeloid leukemia and hyperleukocytosisCancer, 1999
- Acute cardiorespiratory failure as presenting symptom of chronic lymphocytic leukemiaThe Netherlands Journal of Medicine, 1996